Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Is Worth A Shot If You’re A Risk-Capital Investor

In the last trading session, 5.0 million Hepion Pharmaceuticals Inc (NASDAQ:HEPA) shares changed hands as the company’s beta touched 1.59. With the company’s per share price at $0.17 changed hands at -$0.02 or -9.20% during last session, the market valuation stood at $1.81M. HEPA’s last price was a discount, traded about -1858.82% off its 52-week high of $3.33. The share price had its 52-week low at $0.12, which suggests the last value was 29.41% up since then.

Analysts gave the Hepion Pharmaceuticals Inc (HEPA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HEPA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Hepion Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information

Instantly HEPA was in red as seen at the end of in last trading. With action -15.75%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -63.69%, with the 5-day performance at -15.75% in the red. However, in the 30-day time frame, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is 26.44% up.

The consensus price target for the stock as assigned by Wall Street analysts is 70, meaning bulls need an upside of 99.76% from its current market value. According to analyst projections, HEPA’s forecast low is 70 with 70 as the target high. To hit the forecast high, the stock’s price needs a -41076.47% plunge from its current level, while the stock would need to soar -41076.47% for it to hit the projected low.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund. With 48.91 shares estimated at $8348.0 under it, the former controlled 0.70% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.58% of the shares, roughly 40.67 shares worth around $6942.0.